Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 558 participants.
Also called NCT06072001
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 558 participants
- Sponsor
- Apurano Pharmaceuticals GmbH
- Registry
-
NCT06072001
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Unknown status
Technical summary
Registry record NCT06072001. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-02 (actual); primary completion 2024-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
- Condition
- Pain
- Condition
- Pain Syndrome
- Condition
- Pain, Chronic
- Condition
- Chronic Pain
- Condition
- Chronic Pain Syndrome
- Condition
- Neuropathic Pain
- Condition
- Central Neuropathic Pain
- Condition
- Paraplegia
- Condition
- Multiple Sclerosis
- Condition
- Stroke
- Condition
- Phantom Limb Syndrome With Pain
- Condition
- Phantom Pain
- Condition
- Traumatic Brain Injury
- Intervention (Drug)
- Adezunap (AP707)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Apurano Pharmaceuticals GmbH
Record details
- Record id
cardio:ct-nct06072001- Content hash
6fb47683c7a4b90f1cf85e46b30e7cb17e86b4e96191900bb12aeedace110daa